A 10-year open follow-up of eczema and respiratory symptoms in patients with atopic dermatitis treated with topical tacrolimus for the first 4 years

Mandelin, Johanna; Remitz, Anita; Virtanen, Hannele; Malmberg, L. Pekka; Haahtela, Tari; Reitamo, Sakari

doi:10.3109/09546630903493329

Cited by 36 publications

(29 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Clinical studies often focus either on airways (asthma, rhinitis) or skin-related symptoms (atopic eczema, food allergy), although they often have common background. This was exemplified in a study, where treatment of atopic dermatitis decreased respiratory symptoms and bronchial hyperresponsiveness [24]. …”

Section: Discussionmentioning

confidence: 99%

Multimorbidity in Asthma, Allergic Conditions and COPD Increase Disease Severity, Drug Use and Costs: The Finnish Pharmacy Survey

Jantunen

Haahtela

Salimäki³

et al. 2019

Int Arch Allergy Immunol

Self Cite

View full text Add to dashboard Cite

Background: Asthma, allergic conditions, and COPD overlap, but the effect of them and their combinations on disease severity, need for drugs, use of healthcare, and costs is poorly known. Objective: To study how different allergic diseases co-occur in asthma and allergy patients and evaluate the use of medication well as drug and healthcare costs. Methods: Nationwide Allergy Barometer Survey was carried out in the Finnish pharmacies during 1 week in September 2016. Altogether, 956 patients (5–75 years) who purchased asthma or allergy drugs with prescription participated in 351 pharmacies. Results: Of the participants, 78% reported physician-diagnosed asthma, 57% allergic rhinitis, 24% atopic eczema, 21% food allergy, 20% allergic conjunctivitis, 8% anaphylaxis, and 8% COPD. One-third of the patients had at least three conditions, and multimorbidity was common across all age groups. Disease severity increased with the number of coexisting conditions, and asthma severity also with age. Patients with asthma alone used on average 3.8 drugs with the annual costs of EUR 661. This increased to 4.9 drugs and EUR 847 in asthmatics with multimorbidity. For all participants, costs of drugs and healthcare services together during the preceding year were on average EUR 1,214, of which 56% were drug costs. The costs doubled to EUR 2,714 in 65 subjects (7%) who had both asthma and COPD. Conclusions: In asthma and allergy, multimorbidity and polypharmacy are major concerns. Disease severity, drug use, and costs increased with multimorbid conditions. To reduce the burden, allergy management should be better integrated and more comprehensive.

show abstract

Section: Discussionmentioning

confidence: 99%

Multimorbidity in Asthma, Allergic Conditions and COPD Increase Disease Severity, Drug Use and Costs: The Finnish Pharmacy Survey

Jantunen

Haahtela

Salimäki³

et al. 2019

Int Arch Allergy Immunol

Self Cite

View full text Add to dashboard Cite

show abstract

“…In addition to the best results in quality of life and satisfaction parameters, this subgroup also presented the second highest score for patient-relevant benefit (PBI = 2.6). Calcineurin inhibitors are already known as very sufficient patient-oriented therapies with long-term clearance rates [46]. Despite these excellent results, in case of current monotherapy, tacrolimus was ranked in only 60.7% and pimecrolimus in 47.2% of cases as a successful or very successful treatment when considering a 5-year retrospective horizon.…”

Section: Discussionmentioning

confidence: 99%

Therapeutic Benefits in Atopic Dermatitis Care from the Patients' Perspective: Results of the German National Health Care Study ‘Atopic Health'

Steinke

Langenbruch²,

Ständer³

et al. 2014

Dermatology

View full text Add to dashboard Cite

Background/Aims: Numerous therapies are recommended to treat atopic dermatitis. The German national health care study ‘Atopic Health' generated nationwide data on the care situation from the patients' perspective. Methods: Data for 1,678 adult patients were collected within a retrospective cohort study throughout the year 2010. Six scores to capture satisfaction with care, quality of life (Dermatology Life Quality Index, EQ-5D-VAS), therapeutic success and benefits (Patient Benefit Index) were analyzed using descriptive methods and analysis of variance. Results: 82.1% of patients were highly satisfied with their treatment. Topical corticosteroids and climate therapies were associated with the best success ratings. Quality of life was moderately impaired (mean Dermatology Life Quality Index 8.5 ± 6.5). 88.4% of the patients indicated a relevant therapeutic benefit (Patient Benefit Index ≥1) with significantly better scores for topical immunomodulating therapies and climate therapies. Conclusion: The most frequently applied therapies presented pleasant success and benefit ratings, even if quality of life could be improved for more than one third of patients.

show abstract

“…25 However, other eczema treatments might show promise in alleviating symptoms of established asthma, as highlighted in a recent study of the treatment of adult eczema with topical tacrolimus. 26 Biological plausibility for eczema as a cause of airway inflammation has been indicated by recent laboratory and genetic studies. Demehri et al, 13 using a murine model, demonstrated that the atopic march of eczema to asthma could be arrested by blocking the actions of thymic stromal lymphopoietin.…”

Section: Discussionmentioning

confidence: 99%

Childhood eczema and rhinitis predict atopic but not nonatopic adult asthma: A prospective cohort study over 4 decades

Martin

Matheson

Gurrin

et al. 2011

Journal of Allergy and Clinical Immunology

View full text Add to dashboard Cite

A 10-year open follow-up of eczema and respiratory symptoms in patients with atopic dermatitis treated with topical tacrolimus for the first 4 years

Abstract: The long-term, effective treatment of patients with AD may have a beneficial effect on affected BSA, respiratory symptoms, and serum IgE.

Cited by 36 publications

References 13 publications

Multimorbidity in Asthma, Allergic Conditions and COPD Increase Disease Severity, Drug Use and Costs: The Finnish Pharmacy Survey

Multimorbidity in Asthma, Allergic Conditions and COPD Increase Disease Severity, Drug Use and Costs: The Finnish Pharmacy Survey

Therapeutic Benefits in Atopic Dermatitis Care from the Patients' Perspective: Results of the German National Health Care Study ‘Atopic Health'

Childhood eczema and rhinitis predict atopic but not nonatopic adult asthma: A prospective cohort study over 4 decades

Contact Info

Product

Resources

About